Featured Research

from universities, journals, and other organizations

Use of low-toxicity conditioning regimen prior to cell transplantation appears promising for older adults with blood, bone marrow cancers

Date:
November 1, 2011
Source:
JAMA and Archives Journals
Summary:
Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a new study.

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the Nov. 2 issue of JAMA.

"Increasing age has been historically implicated in higher mortality after high-dose allogeneic HCT for patients with hematologic malignancies [cancers of the blood or bone marrow]. Such transplants are preceded by intense, cytotoxic [toxic to cells] conditioning regimens aimed at reducing tumor burden. The risk of organ toxicities has limited the use of high-dose regimens to younger patients in good medical condition. Therefore, age cutoffs of 55 to 60 years have been in place for decades for high-dose HCT. This excluded the vast majority of patients from allogeneic HCT, given that median [midpoint] ages of patients at diagnoses of most hematologic malignancies range from 65 to 70 years," according to background information in the article.

To address this limitation, a nonmyeloablative (an approach using lower doses of chemotherapy and/or radiation that does not lead to eradication of all bone marrow cells prior to stem cell transplant) conditioning regimen for allogeneic HCT was developed. The regimen relies on graft-vs.-tumor effects to cure cancer and consists of the chemotherapy drug fludarabine and a low dose of total-body irradiation before HCT and a course of immunosuppression. "This regimen has allowed extension of allogeneic HCT to a previously unserved population of older or medically infirm patients," the authors write.

Mohamed L. Sorror, M.D., M.Sc., of the Fred Hutchinson Cancer Research Center, Seattle, and colleagues analyzed the outcomes of older patients with advanced hematologic malignancies who received minimally toxic nonmyeloablative allogeneic HCT. From 1998 to 2008, 372 patients ages 60 to 75 years (median age, 64 years) were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, before related (n = 184) or unrelated (n = 188) donor transplants. They also received postgrafting immunosuppression therapy. The primary outcomes measured for the study were overall and progression-free survival.

As of June 23, 2010, 133 of the 372 patients were alive, with a median follow-up of 55 months. Overall, disease progression or relapse has been the most common cause of death (n = 135). Nonrelapse deaths occurred among 104 patients, mainly due to infections, graft-vs.-host disease (GVHD), and multi-organ failure. Five-year rates of overall survival and progression-free survival were 35 percent and 32 percent, respectively. The overall 5-year cumulative incidence of relapse was 41 percent.

Cumulative incidences for nonrelapse mortality at 5 years were comparable among the 3 age groups (27 percent for patients ages 60-64 vs. 26 percent for those ages 65-69 vs. 31 percent for those 70 or older). Five-year rates of overall survival were 38 percent for patients ages 60 through 64, 33 percent for those ages 65 through 69, and 25 percent for those 70 years or older.

Also, comorbid conditions and risks for disease relapse, but not increasing age, were associated with worse outcomes. More than half of the older patients were never hospitalized, and two-thirds of survivors experienced eventual resolution of their chronic GVHD with return to normal or near-normal physical function.

"While there is much room for improvement, particularly with regard to relapse, these results are encouraging given the poor outcomes with nontransplantation treatments, especially for patients with high-risk acute myeloid leukemia, fludarabine-refractory chronic lymphocytic leukemia, or progressive lymphoma. The older population is increasing; demographic changes in the United States suggest that 20 percent of the population will be 65 years or older by 2030. Furthermore, increases of up to 77 percent in the number of newly diagnosed hematologic malignancies among the older population are expected to occur in the next 20 years. Greater age is also associated with increased medical comorbid conditions. Thus, establishing treatment options with curative outcomes and near-normal long-term physical function have become an important future goal for older patients with hematologic malignancies," the authors write.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. M. L. Sorror, B. M. Sandmaier, B. E. Storer, G. N. Franke, G. G. Laport, T. R. Chauncey, E. Agura, R. T. Maziarz, A. Langston, P. Hari, M. A. Pulsipher, W. Bethge, F. Sahebi, B. Bruno, M. B. Maris, A. Yeager, F. B. Petersen, L. Vindelov, P. A. McSweeney, K. Hubel, M. Mielcarek, G. E. Georges, D. Niederwieser, K. G. Blume, D. G. Maloney, R. Storb. Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. JAMA: The Journal of the American Medical Association, 2011; 306 (17): 1874 DOI: 10.1001/jama.2011.1558
  2. S. Mineishi. Overcoming the Age Barrier in Hematopoietic Stem Cell Transplantation: Progress, but Still a Long Way to Go. JAMA: The Journal of the American Medical Association, 2011; 306 (17): 1918 DOI: 10.1001/jama.2011.1612

Cite This Page:

JAMA and Archives Journals. "Use of low-toxicity conditioning regimen prior to cell transplantation appears promising for older adults with blood, bone marrow cancers." ScienceDaily. ScienceDaily, 1 November 2011. <www.sciencedaily.com/releases/2011/11/111101171029.htm>.
JAMA and Archives Journals. (2011, November 1). Use of low-toxicity conditioning regimen prior to cell transplantation appears promising for older adults with blood, bone marrow cancers. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/11/111101171029.htm
JAMA and Archives Journals. "Use of low-toxicity conditioning regimen prior to cell transplantation appears promising for older adults with blood, bone marrow cancers." ScienceDaily. www.sciencedaily.com/releases/2011/11/111101171029.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Age No Longer a Barrier to Stem Cell Transplantation for Older Patients

Nov. 1, 2011 Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins